48
5
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP2018L |
GIP (human) acetate
GIP (human) acetate(100040-31-1 Free base) |
IGF-1R | Tyrosine Kinase/Adaptors |
GIP (human) acetate 是葡萄糖依赖性胰岛素分泌的刺激剂和胃酸分泌的弱抑制剂。 GIP (human) acetate 在脂质代谢和肥胖的发展中起着至关重要的作用。 | |||
TP2017L |
GIP (1-39) acetate
GIP (1-39) acetate(725474-97-5 Free base) |
Others | Others |
GIP (1-39) acetate 是一种从猪肠道中纯化的胃抑制肽 (GIP),可刺激胰岛素分泌。 | |||
T37588L |
GIP (1-30) amide, porcine acetate
|
IGF-1R | Tyrosine Kinase/Adaptors |
GIP (1-30) amide, porcine acetate 是完全葡萄糖依赖性促胰岛素多肽 (GIP) 受体的激动剂。它可弱抑制胃酸分泌,强烈刺激胰岛素。 | |||
TP2020L |
[Pro3]-GIP (Mouse) acetate
|
Others | Others |
[Pro3]-GIP (Mouse) acetate 是鼠源[Pro3]-GIP。[Pro3]-GIP 是一种 GIP receptor 拮抗剂。 | |||
TP2018 |
GIP, human
GIP (human),抑胃肽 |
||
Potent insulinotropic hormone synthesized by duodenal K-cells. High affinity GIP receptor agonist (EC50 = 0.81 nM) that inhibits gastric acid secretion and stimulates pancreatic insulin release in response to glucose. Also affects lipid metabolism and dis | |||
T37589L |
GIP (3-42), human acetate
GIP (3-42), human acetate(1802086-25-4 Free base) |
IGF-1R | Tyrosine Kinase/Adaptors |
GIP (3-42), human acetate 是葡萄糖依赖性促胰岛素多肽 (GIP) 受体的拮抗剂,可调节体内胰岛素分泌和 GIP 代谢。 | |||
TP1584 |
GIP (1-30) amide,human
GIP (1-30) amide (Human) |
||
GIP (1-30) amide (Human) is an insulin-dependent glucose-dependent polypeptide.The sugar-dependent insulin polypeptide (GIP) is an insulin secreting hormone, which can stimulate the secretion of insulin and reduce the occurrence of postpranal-glycemic dis | |||
T37589 |
GIP (3-42), human
Gastric Inhibitory Polypeptide (3-42) (human) |
IGF-1R | Tyrosine Kinase/Adaptors |
GIP (3-42), human (Gastric Inhibitory Polypeptide (3-42) (human)) 是一种多肽,可充当葡萄糖依赖性促胰岛素多肽 (GIP) 受体拮抗剂,在体内调节胰岛素分泌和 GIP 的代谢作用,可用于研究2型糖尿病。 | |||
TP2019 |
[D-Ala2]-GIP (human)
|
||
Highly potent GIP receptor agonist (EC50 = 630 ± 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor. Improves glucose tolerance, insul | |||
T37601 |
GIP (1-30) amide, porcine TFA
|
||
GIP (1-30) amide, porcine TFA is a high-affinity full agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, having a similar potency as the native GIP(1-42) [1]. Furthermore, GIP (1-30) amide, porcine displays weak inhibitory effects on gastric acid secretion while exhibiting potent insulin-stimulating properties. | |||
TP2017 |
GIP (1-39)
|
||
Endogenous truncated form of the incretin hormone GIP. More potent at stimulating glucose-dependent insulin secretion from rat pancreatic β-cells than GIP. | |||
TP2021 |
[Pro3]-GIP (Rat)
|
||
High affinity rat GIP receptor partial agonist (Kd = 13 nM). Increases cAMP accumulation in COS-7 cells transfected with rat GIP receptor, while also acting as a competitive antagonist of GIP. | |||
TP2020 |
[Pro3]-GIP (Mouse)
|
||
GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insul | |||
T37588 |
GIP (1-30) amide, porcine
|
||
This GIP fragment has potent insulinotropic activity in the isolated, perfused rat pancreas but greatly reduced somatostatinotropic activity in the isolated perfused rat stomach. The site responsible for insulinotropic activity apparently lies between residues 19 and 30 of GIP. | |||
TP2019L |
[D-Ala2]-GIP (human) acetate(444073-04-5 Free base)
|
||
[D-Ala2]-GIP (human) acetate(444073-04-5 Free base) 是一种高效的 GIP 受体激动剂 (EC50 = 630 ± 119 pM)。 在表达野生型 GIP 受体的细胞中,与天然 GIP 相比,[D-Ala2]-GIP (human) acetate 显示出同等的 cAMP 刺激特性,并提高了对酶促降解的抵抗力。 [D-Ala2]-GIP (human) acetate 可改善各种肥胖和糖尿病动物模型的葡萄糖耐量、胰岛素释放和认知功能。 [D-Ala2]-GIP (human) acetate 在 PD 的 MPTP 模型中显示出神经保护作用。 | |||
TP1566 |
GIP (1-30) amide (Human) (TFA)
|
||
GIP (1-30) amide (Human) TFA is a glucose-dependent insulinotropic polypeptide fragment. Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. | |||
T82317 |
GIP, rat
|
||
GIP, rat 是一种由十二指肠和空肠 K 细胞在食物摄入后分泌的具有生物活性的肽,由 42 个氨基酸组成。作为肠促胰岛素激素肽家族的一员,GIP 与另一激素 GLP 共同负责刺激胰岛 β 细胞分泌胰岛素,并促进 β 细胞的增殖与存活。近期研究显示GIP 在调控脂质平衡及肥胖发病机制中发挥重要作用。 | |||
T82316 |
GIP, rat TFA
|
||
GIP, rat TFA 是一种源自大鼠的生物活性肽。GIP(Glucose-dependent Insulinotropic Polypeptide,又名 Gastric Inhibitory Polypeptide)是由十二指肠与空肠中的K细胞在摄食后释放的一种含42个氨基酸的多肽。作为肠促胰岛素激素肽家族的一部分,GIP和GLP(Glucagon-Like Peptide)共同调控胰岛β细胞的胰岛素分泌,并可能促进β细胞扩增及存活。此外,近期研究显示GIP参与调节脂质平衡,并可能在肥胖的病理生理中扮演角色。 | |||
T76313 |
(Pro3) GIP, human
|
||
(Pro3) GIP, human ((Pro3)Gastric Inhibitory Peptide, human) 是一种有效、稳定和特异性的人 GIP 受体完全激动剂。(Pro3) GIP, human 对人 GIPR 具有高结合亲和力,Ki/ Kd 值为 0.90 nM。(Pro3) GIP, human 可用于肥胖相关糖尿病的研究。 | |||
T78543 |
Acetyl Gastric Inhibitory Peptide (human) TFA
Human N-acetyl GIP TFA |
||
AcetylGastric Inhibitory Peptide(human) TFA 是一种葡萄糖依赖性胰岛素释放多肽的改性脂肪酸衍生物,具有增强的抗高血糖和促胰岛素作用。它主要用于糖尿病、胰岛素抵抗和肥胖的科研领域。 | |||
T75757 |
GIP, human TFA
|
||
GIP, human TFA 是一种42个氨基酸构成的肽类激素,促进葡萄糖依赖性胰岛素释放,同时轻度抑制胃酸分泌。该激素由肠K细胞释放,响应营养摄入。 | |||
T83696 |
Gastric Inhibitory Peptide 1 (3-42) (human) TFA
Glucose-dependent Insulinotropic Polypeptide 3-42,GIP-1 (3-42) |
||
胃抑制肽1(GIP-1) (3-42)是肠促胰岛素激素GIP的一个肽段,同时也是GIP受体的拮抗剂。它通过血清二肽基肽酶4(DDP-4)从GIP中形成。GIP-1 (3-42) (100 nM)在减少BRIN-BD11胰腺细胞的胰岛素分泌方面起作用。在以25 nmol/kg剂量给药的ob/ob糖尿病小鼠模型中,它能增加血浆葡萄糖水平并降低血浆胰岛素水平。 | |||
T83710 |
Gastric Inhibitory Peptide (22-51) (human) TFA
GIP (22-51),Glucose-dependent Insulinotropic Peptide (22-51) |
||
胃抑制肽(GIP) (22-51) 是一种具有30个氨基酸的前动脉硬化肽,对应于GIP前体蛋白proGIP的第22至51个氨基酸残基,已在人类血浆中发现。在1 µM的浓度下使用,该肽能引起在巨峰细胞分化的THP-1细胞和分离的人类主动脉内皮细胞中IκB-α的降解和NF-κB的核转移。在体内,GIP (22-51) 增加了ApoE-/-小鼠的动脉粥样硬化病变面积和斑块形成。 | |||
T83694 |
Gastric Inhibitory Peptide (1-42) (porcine) TFA
GIP (1-42),Glucose-dependent Insulinotropic Polypeptide (1-42) |
||
胃抑制肽(GIP) (1-42)是一种内源性的42氨基酸肽类肠促素激素,能诱导胰岛素分泌。该激素在肠道神经内分泌K细胞和颌下腺中表达,并在餐后释放到循环中。GIP (1-42)抑制由组胺、五肽和胰岛素引起的胃酸和胃蛋白酶分泌,增加葡萄糖诱导的胰岛素释放,并在大鼠中刺激胃排空。 | |||
T76041 |
GIP (1-30) amide,human acetate
|
||
GIP (1-30) amide, human acetate 为葡萄糖依赖性促胰岛素多肽(GIP)的片段,作为一种肠降血糖素激素,它能在10^-9至10^-6M的剂量范围内,依赖剂量地促进胰岛素的分泌,并有效减缓餐后血糖波动。 | |||
T75150 | GIP/GLP-1 dual receptor agonist-1 | ||
GIP/GLP-1 dual receptor agonist-1 (化合物 4) 是一种 GIP/GLP-1双受体激动剂。GIP/GLP-1 dual receptor agonist-1 可用于代谢紊乱和脂肪肝病,包括非酒精性脂肪性肝炎 (NASH)、非酒精性脂肪性肝病 (NAFLD) 的研究。 | |||
T7284 |
Argipressin acetate (113-79-1(free base))
|
Others | Others |
Vasopressin acetate (113-79-1(free base)) 是一种具有血管收缩和抗利尿活性的肽激素,可与血管精氨酸加压素受体 V1 结合,在 A7r5 大鼠主动脉平滑肌细胞和新生大鼠心肌细胞中的 Kd 值分别为 1.31 和 1.44 nM。 | |||
T7434 |
Argipressin
Arg8-vasopressin,Vasopressin,醋酸精氨酸加压素,精氨加压素,AVP |
Vasopressin Receptor | GPCR/G Protein |
Argipressin (Vasopressin) 是一种具有血管收缩和抗利尿活性的肽激素,可与血管精氨酸加压素受体 V1 结合,在 A7r5 大鼠主动脉平滑肌细胞和新生大鼠心肌细胞中的 Kd 值分别为 1.31 和 1.44 nM。 | |||
T130156 | 8,10-Dihydroxy-3-longipinen-5-one, diangeloyl | ||
8,10-Dihydroxy-3-longipinen-5-one, diangeloyl 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T130156。 | |||
TP2450 |
Argipressin, des-glynh2(9)-
9-Deglycinamide-argipressin,(Arg8,de-Gly9)-vasopressin,DEAVP,DGAVP,9-Des-glynh2-argipressin |
||
Argipressin, des-glynh2(9)-, can effect on aggregation of blood platelets. | |||
T75708 |
Argipressin diacetate
|
||
Argipressin (diacetate) (AVP (diacetate),又称antidiuretic hormone (ADH)) 是一种由垂体后叶分泌的含9个氨基酸的神经肽。通过作用于三种G蛋白偶联受体(GPCRs),Avpr1a (V1a)、Avpr1b (V1b) 及Avpr2 (V2),它调控体液平衡、渗透压及心血管系统的生理功能,并可能对中枢代谢过程产生重要影响。 | |||
T3443 |
Argiprestocin
精氨缩宫素,Arginine vasotocin |
Others | Others |
Argiprestocin (Arginine vasotocin) 也称为抗利尿激素,在维持渗透压中起关键作用。它是在大多数哺乳动物中发现的一种神经垂体激素。用于引起血管收缩的药物。 | |||
TP2449 |
Argipressin, ala(10)-
|
||
Argipressin, ala(10)- is a Decapeptide that differs from argipressin in the addition of an N-terminal Ala-residue. | |||
T124669 |
Spongipregnoloside A
|
||
T27580 |
Icofungipen
PLD 118,BAY 10-8888,PLD-118,PLD118,BAY 108888 |
||
Icofungipen is an oral antifungals with active against Candida species. | |||
TP1111L |
Tirzepatide Acetate(2023788-19-2 free base)
|
Glucagon Receptor | GPCR/G Protein |
Tirzepatide Acetate(2023788-19-2 free base) 是一种双重 GIP / GLP-1 受体激动剂。 | |||
TP1111L1 |
Tirzepatide sodium salt
LY-3298176 sodium salt,Tirzepatide sodium salt(2023788-19-2 free base) |
Glucagon Receptor | GPCR/G Protein |
Tirzepatide sodium salt (LY3298176 sodium salt) 是新型 GIP 和 GLP-1 受体双重激动剂,是人类GIP激素的合成肽类似物。Tirzepatide 具有神经保护活性,可以用于预防和治疗 2 型糖尿病和肥胖症。 | |||
TP1111 |
Tirzepatide
LY-3298176 |
Glucagon Receptor | GPCR/G Protein |
Tirzepatide (LY-3298176) 是葡萄糖依赖性多肽 (GIP) 和胰高血糖素样肽-1 (GLP-1) 受体双重激动剂,具有神经保护活性,可改善血压并降低低密度脂蛋白 (LDL) 胆固醇和甘油三酯,可以用于研究糖尿病和肥胖症。 | |||
T0242 |
Sitagliptin
西他列汀,MK0431,西格列汀 |
Proteasome; DPP-4; Autophagy | Autophagy; Proteases/Proteasome; Ubiquitination |
Sitagliptin (MK0431) 是一种有效的 DPP4抑制剂,在 Caco-2 细胞中,IC50值为 19 nM。它是一种新型口服降糖药,可单独使用或与二甲双胍或噻唑烷二酮联合用于治疗 2 型糖尿病。 | |||
T71340 | Mizagliflozin sebacate | ||
Mizagliflozin sebacate is a sodium-glucose transporter inhibitor. It is expected to improve postprandial hyperglycemia by suppressing glucose absorption from the intestine with a novel mechanism of action different from that of conventional alpha-glucosidase inhibitors. Mizagliflozin blocks intestinal glucose absorption and reduce GIP secretion in rats and humans, suggesting SGLT1 glucose transport is critical for GIP release. | |||
T37599 |
DA-JC4
DA-JC4 |
||
DA-JC4 is a compound with dual GLP-1/GIP receptor agonist properties. It is recommended for use in researching neurological diseases and investigating insulin signaling pathways[1][2][3]. | |||
TP1110 |
Tirzepatide hydrochloride
LY3298176 hydrochloride |
||
Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. | |||
T76006 |
Tirzepatide TFA
Tirzepatide TFA(2023788-19-2 free base),LY3298176 TFA |
||
Tirzepatide TFA (LY3298176 TFA) 是葡萄糖依赖性胰岛素营养多肽(GIP)和胰高血糖素样肽-1(GLP-1)受体双重激动剂,有潜力用于 2 型糖尿病的研究。 | |||
T76307 |
[Tyr0] Gastric Inhibitory Peptide (23-42), human
|
||
[Tyr0]Gastric Inhibitory Peptide(23-42), human,属于葡萄糖依赖性促胰岛素多肽(GIP)类,具有抑制胃酸分泌并促进胰岛素释放的功能。它在糖尿病和肥胖症的研究中有应用价值。 | |||
T81214 |
SAR441255
|
||
SAR441255为高效单分子肽GLP-1/GIP/GCG受体激动剂,能平衡激活三种靶受体,表现出高效力。此外,SAR441255对糖尿病肥胖猴子具有显著的急性血糖调节效果。 | |||
T76308 |
Gastric Inhibitory Polypeptide (1-30), porcine
|
||
Gastric Inhibitory Polypeptide (1-30), porcine 缺乏天然胃抑制多肽 (GIP) C 端 12 个氨基酸残基,能够增强胰岛素和生长抑素的释放而发挥生物活性。 | |||
T36760 | KQMEEEAVRLFIEWLKNGGPSSGAPPPS | ||
KQMEEEAVRLFIEWLKNGGPSSGAPPPS is a Exendin-4 peptide derivative. Exendin-4 is a pure GLP-1 receptor agonist. Exendin-4 peptide derivatives are structurally derived from Exendin-4 and may relates to dual GLP-1/glucagon receptor agonists. Their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake. These dual GLP-1/glucagon receptor agonists show reduced activity on the GIP receptor to reduce ... | |||
T82923 |
Bamadutide
SAR425899 |
||
Bamadutide (SAR425899)是一种高效的GLP-1/GIP受体激动剂,主要通过增强β细胞功能和降低葡萄糖吸收速率,从而改善餐后血糖控制。该化合物适用于2型糖尿病的研究。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN5845 |
Neochlorogenic acid methyl ester
5-O-Caffeoylquinic acid methyl ester,Methyl 3-caffeoylquinate,GIP (1-39) acetate(725474-97-5 Free base),Methyl neochlorogenate,新绿原酸甲酯 |
Antioxidant; HBV | Microbiology/Virology; oxidation-reduction |
Neochlorogenic acid methyl ester (5-O-Caffeoylquinic acid methyl ester) 来源于毛蒿和黑色苦莓(Aronia melanocarpa)果实。Neochlorogenic acid methyl ester 显示出抗 HBV 活性、抗氧化活性和醌还原酶活性,CD 为 6.7 μM。 | |||
TN3132 |
5-O-Methyldalbergiphenol
|
Others | Others |
5-O-Methyldalbergiphenol 是一种天然产物,可用于生命科学领域的相关研究。其产品编号为 TN3132,CAS号为 1499946-35-8。 | |||
TN4448 |
Longipedlactone J
|
Others | Others |
Longipedlactone J是一种天然产物,属于五味子科南五味子属,其产品编号为 TN4448,CAS号为 1011762-93-8。Longipedlactone J可用作对照参考。 | |||
TN5700 |
(+)-Dalbergiphenol
(+)-黄檀酚,(R)-Dalbergiphenol |
||
(+)-Dalbergiphenol 是一种天然产物,可用于生命科学领域的相关研究。其产品编号为 TN5700,CAS号为 82358-44-9。 | |||
TN3754 |
Dalbergiphenol
檀木 |
Others | Others |
Dalbergiphenol shows antiosteoporotic activity, dalbergiphenol treatment can effectively prevent OVX-induced increase in bone loss and decrease in bone strength possibly by increasing osteoblastic activities and by decreasing osteoclastic activities. |